DiagnosticsGrowth
Scaled revenue from £90m → £400m
Finance transformation and procurement overhaul; rebuilt FP&A and BI, improved margins and top line.
01Cullbuie
Track record
Diagnostics and Biotech
The Cullbuie team has deep experience in the diagnostics and biotech segments with a combined 10 years in C-Suite leadership within clinical diagnostics and over 10 years experience in advisory with a focus on on life sciences, biotech, and pharmaceutical sectors. A selection of companies and transactions completed across biotech, diagnostics and health is below.
BiotechDiagnosticsHealthtechPrivate EquityTransformation
Clients
Selected Diagnostics and Biotech
Transactions
Selected highlights
01 / 06
Private EquityBuy-side
Private equity group £179 million management buyout of UK pharmaceuticals company
Assisted management with strategic plan for take-private
02Cullbuie
BiotechTransactions
Public Takeover, £29m
Investor materials, data room prep, and LSE compliant communications.
03Cullbuie
TransformationSystems
ERP & reporting overhaul
Consolidated US UK multi-entity finance stack; monthly close reduced from 9 to 5 working days.
04Cullbuie
Diagnostics ServicesNHS JV
£1bn Joint Venture with NHS
Set up TriParty Joint Venture with University College London NHS Trust and Royal Free London NHS Trust as CFO to provide >£100m of acute and community pathology services annually.
05Cullbuie
DiagnosticsGovernment
Pandemic Response Laboratory
Negotiated and built 16,000sqft COVID laboratory in central London for DHSC.
06Cullbuie
Track record